Cargando…

Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen

In a companion paper, we demonstrated that the nucleoside analogue favipiravir (FAV) suppressed Zika virus (ZIKV) replication in three human-derived cell lines—HeLa, SK-N-MC, and HUH-7. Our results revealed that FAV’s effect was most pronounced in HeLa cells. In this work, we aimed to explain variat...

Descripción completa

Detalles Bibliográficos
Autores principales: Franco, Evelyn J., Cella, Eleonora, Tao, Xun, Hanrahan, Kaley C., Azarian, Taj, Brown, Ashley N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224157/
https://www.ncbi.nlm.nih.gov/pubmed/37317316
http://dx.doi.org/10.3390/microorganisms11051342
_version_ 1785050110287151104
author Franco, Evelyn J.
Cella, Eleonora
Tao, Xun
Hanrahan, Kaley C.
Azarian, Taj
Brown, Ashley N.
author_facet Franco, Evelyn J.
Cella, Eleonora
Tao, Xun
Hanrahan, Kaley C.
Azarian, Taj
Brown, Ashley N.
author_sort Franco, Evelyn J.
collection PubMed
description In a companion paper, we demonstrated that the nucleoside analogue favipiravir (FAV) suppressed Zika virus (ZIKV) replication in three human-derived cell lines—HeLa, SK-N-MC, and HUH-7. Our results revealed that FAV’s effect was most pronounced in HeLa cells. In this work, we aimed to explain variation in FAV activity, investigating its mechanism of action and characterizing host cell factors relevant to tissue-specific differences in drug effect. Using viral genome sequencing, we show that FAV therapy was associated with an increase in the number of mutations and promoted the production of defective viral particles in all three cell lines. Our findings demonstrate that defective viral particles made up a larger portion of the viral population released from HeLa cells both at increasing FAV concentrations and at increasing exposure times. Taken together, our companion papers show that FAV acts via lethal mutagenesis against ZIKV and highlight the host cell’s influence on the activation and antiviral activity of nucleoside analogues. Furthermore, the information gleaned from these companion papers can be applied to gain a more comprehensive understanding of the activity of nucleoside analogues and the impact of host cell factors against other viral infections for which we currently have no approved antiviral therapies.
format Online
Article
Text
id pubmed-10224157
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102241572023-05-28 Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen Franco, Evelyn J. Cella, Eleonora Tao, Xun Hanrahan, Kaley C. Azarian, Taj Brown, Ashley N. Microorganisms Article In a companion paper, we demonstrated that the nucleoside analogue favipiravir (FAV) suppressed Zika virus (ZIKV) replication in three human-derived cell lines—HeLa, SK-N-MC, and HUH-7. Our results revealed that FAV’s effect was most pronounced in HeLa cells. In this work, we aimed to explain variation in FAV activity, investigating its mechanism of action and characterizing host cell factors relevant to tissue-specific differences in drug effect. Using viral genome sequencing, we show that FAV therapy was associated with an increase in the number of mutations and promoted the production of defective viral particles in all three cell lines. Our findings demonstrate that defective viral particles made up a larger portion of the viral population released from HeLa cells both at increasing FAV concentrations and at increasing exposure times. Taken together, our companion papers show that FAV acts via lethal mutagenesis against ZIKV and highlight the host cell’s influence on the activation and antiviral activity of nucleoside analogues. Furthermore, the information gleaned from these companion papers can be applied to gain a more comprehensive understanding of the activity of nucleoside analogues and the impact of host cell factors against other viral infections for which we currently have no approved antiviral therapies. MDPI 2023-05-19 /pmc/articles/PMC10224157/ /pubmed/37317316 http://dx.doi.org/10.3390/microorganisms11051342 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Franco, Evelyn J.
Cella, Eleonora
Tao, Xun
Hanrahan, Kaley C.
Azarian, Taj
Brown, Ashley N.
Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen
title Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen
title_full Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen
title_fullStr Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen
title_full_unstemmed Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen
title_short Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen
title_sort favipiravir suppresses zika virus (zikv) through activity as a mutagen
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224157/
https://www.ncbi.nlm.nih.gov/pubmed/37317316
http://dx.doi.org/10.3390/microorganisms11051342
work_keys_str_mv AT francoevelynj favipiravirsuppresseszikaviruszikvthroughactivityasamutagen
AT cellaeleonora favipiravirsuppresseszikaviruszikvthroughactivityasamutagen
AT taoxun favipiravirsuppresseszikaviruszikvthroughactivityasamutagen
AT hanrahankaleyc favipiravirsuppresseszikaviruszikvthroughactivityasamutagen
AT azariantaj favipiravirsuppresseszikaviruszikvthroughactivityasamutagen
AT brownashleyn favipiravirsuppresseszikaviruszikvthroughactivityasamutagen